Ka la 27 Phupu 2023, Lilly o phatlalalitse hore thuto ea Mount-3 ea Tirzepatide bakeng sa ho phekola bakuli ba batenya le thuto ea Mount-4 bakeng sa ho boloka boima ba 'mele ba bakuli ba batenya e fihlile pheletsong ea mantlha le ntlha ea bohlokoa ea bobeli.Ena ke karolo ea boraro le ea bone e atlehileng ea lipatlisiso tse fumanoeng ke Tirzepatide ka mor'a Thaba-1 le Mount-2.
SURMOUNT-3 (NCT04657016) ke teko e laoloang ke li-multicenter, randomized, double-blind, parallel, placebo e ngolisitseng kakaretso ea barupeluoa ba 806 e etselitsoeng ho bontša bophahamo ba Tirzepatide ho feta placebo mabapi le phetoho ea peresente ea phetoho ea boima ba 'mele ka mor'a hore ho be le randomization le peresente ea barupeluoa ba lahlehetsoeng ke ≥5% ka mor'a hore ho be le randomization libeke tse 72.
Liphetho tsa thuto ea SURMOUNT-3 li bonts'itse hore Tirzepatide e fihletse lintlha tsohle, e leng hore kamora libeke tse 72 tsa kalafo ea dosing, bakuli ba sehlopha sa Tirzepatide ba fihletse liperesente tse phahameng tsa ho theola boima ba 'mele ho tloha qalong ho bapisoa le placebo, le liperesente tse phahameng tsa bakuli sehlopheng sa Tirzepatide. e fihletse peresente ea tahlehelo ea boima e kholo ho feta 5%.Lintlha tse khethehileng tsa kliniki li bontšitse hore bakuli ba tšoaroang ka Tirzepatide ba lahlehetsoe ke karolelano ea 21.1% ea boima ba 'mele ho bapisoa le placebo;Ho kopantsoe le nako ea ho kenella ka libeke tse 12, bakuli ba tšoaroang ka Tirzepatide ba ile ba lahleheloa ke karolelano ea karolo ea 26.6 lekholong ea boima ba 'mele ea bona.Ntle le moo, 94.4% ea bakuli ba lahlile ≥5% ea boima ba bona sehlopheng sa Tirzepatide, ha se bapisoa le 10.7% sehlopheng sa placebo.
SURMOUNT-4 (NCT04660643) ke teko e laoloang ke mefuta e mengata, e sa tloaelehang, e sa boneng habeli, e tšoanang, e laoloang ke placebo e ngolisitseng kakaretso ea barupeluoa ba 783 e etselitsoeng ho bontša hore Tirzepatide e ne e phahametse placebo ka peresente ea phetoho ea boima ba 'mele ho 88-beke ea randomization.
Liphello li bontšitse hore ka mor'a nako ea ho foufala habeli ea libeke tse 37 ~ 88, bakuli ba sehlopha sa Tirzepatide ba ile ba lahleheloa ke boima ba 'mele ho feta ba sehlopha sa placebo.Mabapi le polokeho, ha ho lithuto tsa SURMOUNT-3 kapa SURMOUNT-4 tse ileng tsa hlokomela matšoao a macha a tšireletso.
Ho tloha ha ho qalisoa ha Novo Nordisk's blockbuster diet drug Semaglutide, hammoho le tumello e matla ea Musk, e fetohile sehlahisoa sa batho ba tummeng ba Inthanete le morena oa hona joale oa tahlehelo ea boima ba 'mele.Tlhokahalo ea 'maraka ea tahlehelo ea boima e kholo,' me ho na le lithethefatsi tse peli feela tsa ho theola boima ba 'mele tsa GLP-1 hajoale tse rekisoang, Liraglutide le Semaglutide, empa Liraglutide ke tokiso e nkang nako e khuts'oane, e ke keng ea qothisana lehlokoa le litokisetso tse nkang nako e telele mabapi le ho latela mokuli. , 'me lefatše la hona joale la ho lahleheloa ke boima ba nakoana ke la Semaglutide.
Hape morena oa tšimo ea GLP-1, Lilly o lakatsa leoatle le leputsoa la 'maraka oa tahlehelo ea boima ba' mele - kahoo Lilly o ile a qala phephetso le ho becha pele ho Tirzepatide ho hapa sebaka 'marakeng oa tahlehelo ea boima ba' mele.
Tirzepatide ke GIPR/GLP-1R e nang le li-agonists tse peli tsa beke le beke, GIP (insulin e itšetlehileng ka tsoekere e susumetsang polypeptide) ke setho se seng sa lelapa la glucagon peptide, se nang le phello ea ho khothaletsa tlhahiso ea insulin ka mokhoa o itšetlehileng ka insulin le ho susumetsa secretion ea glucagon ka hypoglycemic. state, GIPR/GLP-1R dual agonists e ka hlahisa taolo ea tsoekere ea mali, ho theola boima ba 'mele le litlamorao tse ling ka ho susumetsa litsela tse peli tsa GIP le GLP-1.Tirzepatide e amohetsoe ke FDA ka 2022-5 (lebitso la khoebo: Mounjaro) hore e sebelisoe hammoho le lijo le boikoetliso ho ntlafatsa taolo ea glycemic ho batho ba baholo ba nang le lefu la tsoekere la mofuta oa 2.
Nako ea poso: Sep-18-2023